INDEMNIFICATION AGREEMENTIndemnification Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into as of [ ], 2022, by and between Felicitex Therapeutics Inc., a Delaware corporation (the “Company”) and the undersigned, a director and/or an officer of the Company (“Indemnitee”), as applicable.
INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”), dated [ ], 2022, by and between Felicitex Therapeutics Inc., a Delaware corporation (the “Company”), and the undersigned (the “Director”).
Board of Directors AgreementBoard of Directors Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Pennsylvania
On behalf of Felicitex Therapeutics, Inc. (the “Company”), I am pleased to offer you a position on our Board of Directors for a three year term subject to annual approval of the shareholders.
ContractWarrant Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW.
THIS EXHIBIT HAS BEEN REDACTED TO REMOVE INFORMATION THAT IS NOT MATERIAL AND THAT THE REGISTRANT MUST TREAT AS PRIVATE AND CONFIDENTIAL.** FELICITEX MATERIAL TRANSFER AGREEMENTMaterial Transfer Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Felicitex Material Transfer Agreement (this “Agreement”) is dated July 18, 2022 and is by and between Felicitex Therapeutics, Inc., a Delaware corporation, located at 27 Strathmore Rd, Natick, MA 01760 (“Felicitex”) and Barbara Ann Kaimanos Cancer Institute, a Michigan nonprofit corporation, located at 4100 John R, Detroit, MI 48201 (“Recipient”) (together with Felicitex, “Parties” and each, a “Party”).
SHAREHOLDER LOAN AGREEMENTShareholder Loan Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
IN CONSIDERATION OF the Shareholder lending certain monies (the “Loan”) to the Company, and the Company repaying the Loan to the Shareholder, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
FELICITEX MATERIAL TRANSFER AND ROYALTY AGREEMENTMaterial Transfer and Royalty Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations
This Felicitex Material Transfer and Royalty Agreement (this “Agreement”) is effective the date of full execution by the Parties below and is by and between Felicitex Therapeutics, Inc., a Delaware corporation (“Felicitex”) having a usual place of business at 27 Strathmore Rd., Natick, MA 01760 and Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation having its principal place of business at 1275 York Avenue, New York, NY 10065 (“Recipient” or “MSK”) (together with Felicitex, “Parties” and each, a “Party”).
THIS EXHIBIT HAS BEEN REDACTED TO REMOVE INFORMATION THAT IS NOT MATERIAL AND THAT THE REGISTRANT MUST TREAT AS PRIVATE AND CONFIDENTIAL.**Exclusive License Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of this [ ] day of [ ], 20[ ] (the “Effective Date”) by and between Felicitex Therapeutics, Inc., a corporation duly organized under the laws of the State of Delaware, United States having its principal place of business at One Kendall Square Building 200, B2002, Cambridge, Massachusetts 02139, U.S.A. (“Felicitex”), and Selvita S.A., a Polish corporation, having its principal place of business at Park Life Science, ul. Bobrzyńskiego 14, 30-348 Kraków, Poland (“Selvita”). Felicitex and Selvita are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”.
Agreement and Plan of MergerMerger Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 30, 2021, by and among Felicitex Therapeutics, Inc., a Delaware corporation (“Purchaser”), and TarMeta Biosciences, LLC., a Pennsylvania corporation (“Company”), and Marc Duey and Felix Chapovsky (“Owners,”), collectively, the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
FELICITEX THERAPEUTICS, INC., a Delaware corporation duly organized under law and having an usual place of business at 45 Ridge Road, Newton, MA 02468 (hereinafter referred to as the “COMPANY”)
EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT (this “Agreement”) dated this 30th day of December, 2021Employment Contract • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
March 10, 2022 Dr. Maria Vilenchik 45 Ridge Rd Waban, MA 02468 Dear Masha,Employment Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
RESEARCH COLLABORATION AND OPTION AGREEMENTResearch Collaboration and Option Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS RESEARCH COLLABORATION AND OPTION AGREEMENT (this “Agreement”) is entered into and made effective as of this 1st day of October, 2014 (the “Effective Date”) by and between Felicitex Therapeutics, Inc., a corporation duly organized under the laws of the State of Delaware, United States having its principal place of business at One Kendall Square Building 200, B2002, Cambridge, Massachusetts 02139, U.S.A. (“Felicitex”), and Selvita S.A., a Polish corporation, having its principal place of business at Park Life Science, ul. Bobrzynskiego 14, 30-348 Krakow, Poland (“Selvita”). Felicitex and Selvita are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations
FELICITEX MATERIAL TRANSFER AGREEMENTMaterial Transfer Agreement • August 10th, 2022 • Felicitex Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Felicitex Material Transfer Agreement (this “Agreement”) is dated May 15th, 2021 and is by and between Felicitex Therapeutics, Inc., a Delaware corporation (“Felicitex”) at 27 Strathmore Rd., Natick, MA, USA and UAB DolceRx Baltika (“DolceRx”), a Lithuanian corporation (“Recipient”) at Pramones str. 21, Klaipeda, Lithuania (together with Felicitex, “Parties” and each, a “Party”).
